Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries (Q36101210)

12 August 2017

1 reference

title

Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries (English)

1 reference

12 August 2017

Richard I Walker

1

1 reference

PubMed ID

15837361

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

23

1 reference

12 August 2017

26

1 reference

12 August 2017

3369-3385

1 reference

Microbial-gut interactions in health and disease. Progress in enteric vaccine development

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Diarrhoea: a significant worldwide problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Long-term shifts in patterns of antibiotic resistance in enteric bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Early childhood diarrhoea and helminthiases associate with long-term linear growth faltering.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Epidemiology of bacterial resistance in gastro-intestinal pathogens in a tropical area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Diarrhea as a Cause and an Effect of Malnutrition: Diarrhea Prevents Catch-up Growth and Malnutrition Increases Diarrhea Frequency and Duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Magnitude and impact of diarrheal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Diarrheal disease during Operation Desert Shield

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Vaccines against human enteric bacterial pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Polymicrobial aetiology of travellers' diarrhoea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Pathology of the motor-sensory axonal Guillain-Barré syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Diagnosis and management of dysentery by community health workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Epidemic Shiga Bacillus Dysentery in Central America. II. Epidemiologic Studies in 1969

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Plasmid characterisation in the investigation of an epidemic caused by multiply resistant Shigella dysenteriae type 1 in Central Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Epidemic bacillary dysentery in West Bengal, India, 1984

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

A review of bacterial resistance to antimicrobial agents in tropical countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

An outbreak of diarrhoeal disease attributed to Shigella sonnei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Preclinical evaluation of microencapsulated CFA/II oral vaccine against enterotoxigenic E. coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Transcutaneous immunization: a human vaccine delivery strategy using a patch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Typhoid fever in children aged less than 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Recombinant Norwalk virus-like particles given orally to volunteers: phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Immune responses and protection obtained with rotavirus VP6 DNA vaccines given by intramuscular injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Helicobacter in the developing world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Association between Helicobacter pylori infection and increased risk of typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Extended recombinant bacterial ghost system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Production of Vibrio cholerae ghosts (VCG) by expression of a cloned phage lysis gene: potential for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Activation, stimulation and uptake of bacterial ghosts in antigen presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Immunogenicity of Vibrio cholerae ghosts following intraperitoneal immunization of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

CpG DNA: a novel immunomodulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Bacteria-derived particles as adjuvants for non-replicating nasal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

New strategies for using mucosal vaccination to achieve more effective immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Specific immune response in humans following rectal delivery of live typhoid vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Experimental Campylobacter jejuni infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Persistent Campylobacter jejuni infection in an immunocompromised patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Structural and antigenic characteristics of Campylobacter coli FlaA flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Immunity in Shigellosis. I. Response of Man to Attenuated Strains of Shigella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Expression of Shigella sonnei lipopolysaccharide in Vibrio cholerae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Role of Vibrio cholerae O139 surface polysaccharides in intestinal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

Mechanisms and impact of enteric infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Epidemiologic aspects of shigellosis and other causes of dysentery in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Immune response to Campylobacter jejuni and Campylobacter coli in a cohort of children from birth to 2 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Human antibody response to outer membrane proteins of Campylobacter jejuni during infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Outer membrane characteristics of Campylobacter jejuni

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Roles of different coli surface antigens of colonization factor antigen II in colonization by and protective immunogenicity of enterotoxigenic Escherichia coli in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.029

7 January 2021

10.1016/J.VACCINE.2004.12.029

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15837361